<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Rule 13d-101)
Information to be included in Statements filed Pursuant
To Rule 13d-1(a) and Amendments Thereto Filed Pursuant To
Rule 13d-2(a)
IMPAX LABORATORIES INC.
- --------------------------------------------------------------------------------
(Name of Issuer)
(Formerly Global Pharmaceutical Corporation)
COMMON STOCK, $.01 PAR VALUE
- --------------------------------------------------------------------------------
(Title of Class of Securities)
45256B101
- --------------------------------------------------------------------------------
(CUSIP Number)
LAURIE A. MILLER, ESQ.
LAW OFFICE OF LAURIE MILLER
3542 OAK KNOLL DRIVE
REDWOOD CITY, CA 94062
(650) 361-8141
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
DECEMBER 14, 1999
- --------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following
box. [ ]
Note: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See Rule 13d-7(b) for other
parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
2
<PAGE>
_______________________________________________________________________________
CUSIP No. 45256B 10 1 SCHEDULE 13D Page 1 of 3 Pages
_______________________________________________________________________________
1 NAME OF REPORTING PERSONS
S.S OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
LAURIE A. MILLER
______________________________________________________________________________
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [X]
(b) [ ]
______________________________________________________________________________
3 SEC USE ONLY
______________________________________________________________________________
4 SOURCE OF FUNDS*
SC
______________________________________________________________________________
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
______________________________________________________________________________
6 CITIZENSHIP OR PLACE OF ORGANIZATION
U.S.A.
_______________________________________________________________________________
| |
NUMBER OF | 7 | SOLE VOTING POWER
SHARES | | 4,013,635 shares of Common Stock (See Item 5)
BENEFICIALLY |_____|________________________________________________________
OWNED BY | |
EACH | 8 | SHARED VOTING POWER
REPORTING | | 0 shares of Common Stock (See Item 5)
PERSON WITH |_____|________________________________________________________
| |
| 9 | SOLE DISPOSITIVE POWER
| | 4,013,635 shares of Common Stock (See Item 5)
|_____|________________________________________________________
| |
| 10 | SHARED DISPOSITIVE POWER
| | 0 shares of Common Stock (See Item 5)
_______________|_____|_________________________________________________________
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
77,391(**) shares of Common Stock (See Item 5)
______________________________________________________________________________
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* [X]
______________________________________________________________________________
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0.3% of Common Stock (See Item 5)
______________________________________________________________________________
14 TYPE OF REPORTING PERSON*
IN
______________________________________________________________________________
* SEE INSTRUCTION BEFORE FILLING OUT
(**) Excludes 3,936,244 shares of common stock owned by the Chiin Hsiao
Children Irrecocable Trust and the Hsu Children Irrevocable Trust, for
which Laurie A. Miller, who is general counsel to Impax, serves as
trustee. Ms. Miller disclaims beneficial ownership of these shares.
3
<PAGE>
CUSIP No. 45256B 10 1 SCHEDULE 13D Page 2 of 3 Pages
_______________________________________________________________________________
1 NAME OF REPORTING PERSONS
S.S OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
CHIN HSIUNG (CHARLES) HSIAO CHILDREN IRREVOCABLE TRUST
______________________________________________________________________________
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [X]
(b) [ ]
______________________________________________________________________________
3 SEC USE ONLY
______________________________________________________________________________
4 SOURCE OF FUNDS*
SC
______________________________________________________________________________
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
______________________________________________________________________________
6 CITIZENSHIP OR PLACE OF ORGANIZATION
CALIFORNIA, U.S.A.
_______________________________________________________________________________
| |
NUMBER OF | 7 | SOLE VOTING POWER
SHARES | | 2,601,924 shares of Common Stock (See Item 5)
BENEFICIALLY |_____|________________________________________________________
OWNED BY | |
EACH | 8 | SHARED VOTING POWER
REPORTING | | 0 shares of Common Stock (See Item 5)
PERSON WITH |_____|________________________________________________________
| |
| 9 | SOLE DISPOSITIVE POWER
| | 2,601,924 shares of Common Stock (See Item 5)
|_____|________________________________________________________
| |
| 10 | SHARED DISPOSITIVE POWER
| | 0 shares of Common Stock (See Item 5)
_______________|_____|_________________________________________________________
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,601,924 shares of Common Stock (See Item 5)
______________________________________________________________________________
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* [ ]
______________________________________________________________________________
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
10.5% of Common Stock (See Item 5)
______________________________________________________________________________
14 TYPE OF REPORTING PERSON*
00
______________________________________________________________________________
*SEE INSTRUCTIONS BEFORE FILLING OUT
4
<PAGE>
CUSIP No. 45256B 10 1 SCHEDULE 13D Page 2 of 3 Pages
_______________________________________________________________________________
1 NAME OF REPORTING PERSONS
S.S OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
CHUNG-CHAING (LARRY) HSU CHILDREN IRREVOCABLE TRUST
______________________________________________________________________________
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [X]
(b) [ ]
______________________________________________________________________________
3 SEC USE ONLY
______________________________________________________________________________
4 SOURCE OF FUNDS*
SC
______________________________________________________________________________
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
______________________________________________________________________________
6 CITIZENSHIP OR PLACE OF ORGANIZATION
CALIFORNIA, U.S.A.
_______________________________________________________________________________
| |
NUMBER OF | 7 | SOLE VOTING POWER
SHARES | | 1,334,320 shares of Common Stock (See Item 5)
BENEFICIALLY |_____|________________________________________________________
OWNED BY | |
EACH | 8 | SHARED VOTING POWER
REPORTING | | 0 shares of Common Stock (See Item 5)
PERSON WITH |_____|________________________________________________________
| |
| 9 | SOLE DISPOSITIVE POWER
| | 1,334,320 shares of Common Stock (See Item 5)
|_____|________________________________________________________
| |
| 10 | SHARED DISPOSITIVE POWER
| | 0 shares of Common Stock (See Item 5)
_______________|_____|_________________________________________________________
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,344,320 shares of Common Stock (See Item 5)
______________________________________________________________________________
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* [ ]
______________________________________________________________________________
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
5.4% of Common Stock (See Item 5)
______________________________________________________________________________
14 TYPE OF REPORTING PERSON*
00
______________________________________________________________________________
*SEE INSTRUCTIONS BEFORE FILLING OUT
5
<PAGE>
SCHEDULE 13D
FILED PURSUANT TO RULE 13D-1
OF THE GENERAL RULES AND REGULATIONS UNDER
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED
Effective December 14, 1999, Impax Pharmaceuticals, Inc., a California
corporation ("Impax"), merged with and into Global Pharmaceutical Corporation, a
Delaware corporation ("Global"), and in connection therewith, Global changed its
name to Impax Laboratories, Inc. ("Issuer"). The purpose of this Schedule 13D is
to report that, as a result of the Merger, the "Reporting Persons", in the
aggregate, own 16.2% percent of the Common Stock, $.01 par value (the "Common
Stock"), of the Issuer.
Responses to each item below are incorporated by reference into each
other item, as applicable.
Item 1. Security and Issuer.
This Schedule 13D relates to Common Stock of the Issuer. The address of
the Issuer's principal executive office is 30831 Huntwood Avenue, Hayward, CA
94544.
Item 2. Identity and Background.
This statement is being filed pursuant to a Joint Filing Agreement
(attached as Exhibit 1 and incorporated herein by reference) by (i) Laurie A.
Miller ("Ms. Miller"), (ii) Chiin Hsiung (Charles) Hsiao Children Irrevocable
Trust (the "Hsiao Trust") and (iii) Chung-Chiang (Larry) Hsu Children
Irrevocable Trust (the "Hsu Trust").
The information required by this Item for each of the Reporting Persons
is set forth in Appendix 1 hereto. The information required by this Item for
each officer, director and partner and each controlling person, if any, of such
Reporting Persons is set forth in Appendix 2 hereto.
During the last five years prior to the date of this filing, none of
the Reporting Persons or persons identified in Appendix 1 or Appendix 2 has been
convicted in a criminal proceeding (excluding traffic violations or similar
misdemeanors) or has been a party to a civil proceeding of a judicial or
administrative body of competent jurisdiction ending in a judgment, decree or
final order enjoining future violations or prohibiting or mandating the
activities subject to, federal or state securities laws or finding a violation
with respect to such laws.
Item 3. Source and Amount of Funds or Other Consideration.
Global and Impax entered into an Agreement and Plan of Merger, dated as
of July 26, 1999 ("Merger Agreement"), pursuant to which Impax would merge into
Global, with Global being the surviving corporation. The Merger of Impax into
Global was consummated on December 14, 1999.
The Issuer's corporate existence was not affected by the Merger, but
its certificate of incorporation was amended to increase the number of shares of
Common Stock Issuer is authorized to issue and to change the name of the
combined company to Impax Laboratories, Inc.
6
<PAGE>
Effective with the Merger, the following shares and all rights with
respect to those shares were converted into capital stock of the Issuer as
described below:
Each outstanding share of Impax common stock, Series A preferred stock
and Series B preferred stock was converted into 3.3358 shares of Issuer Common
Stock;
Each outstanding share of Impax Series C Preferred Stock was converted
into 5.849 shares of the Issuer's Common Stock;
Every 20 outstanding shares of Impax Series D Preferred Stock was
converted into one share of the Issuer's Series 1-B Preferred Stock;
Each outstanding share of Global Series C Preferred Stock was converted
into 50 shares of Issuer Common Stock; and
Each outstanding share of Global Series D Preferred Stock was converted
into one share of Issuer's Series 1-A Preferred Stock.
The Chiin Hsiao Children Irrevocable Trust (the "Hsiao Trust") was the
record and beneficial owner of 780,000 shares of Common Stock of Impax.
Consequently, as a result of the Merger, the Hsiao Trust is the record and
beneficial owner of 2,601,924 shares of Common Stock of Issuer.
The Hsu Children Irrevocable Trust (the "Hsu Trust"), was the record
and beneficial owner of 400,000 shares of Common Stock of Impax. Consequently,
as a result of the Merger, the Hsu Trust is the record and beneficial owner of
1,334,320 shares of Common Stock of Issuer. The Hsiao Trust and the Hsu Trust
are collectively referred to herein as the "Trusts".
Ms. Miller was the record and beneficial owner of 15,000 shares of
Series A Preferred Stock of Impax and 8,200 shares of Common Stock of Impax.
Consequently, as a result of the Merger, Ms. Miller is the record and beneficial
owner of 77,391 shares of Common Stock of Issuer.
Additionally, Ms. Miller is the sole trustee of each of the Trusts and
may be deemed to be the beneficial owner of 3,936,244 shares of Common Stock of
Issuer held by the Trusts. Ms. Miller disclaims beneficial ownership of the
shares held by such Trusts.
Item 4. Purpose of Transaction.
a) The Series 1-B Preferred Stock and Common Stock deemed to be
beneficially owned by the Reporting Persons were acquired for, and are being
held for, investment purposes. The Reporting Persons may dispose of or acquire
securities of the Issuer, including Series 1 Preferred Stock and Common Stock,
depending upon the position of the market, the Issuer and other factors.
Except as set forth above, none of the Reporting Persons nor, to the
best of their knowledge, any person listed in Appendix I hereto, has any plans
or proposals which relate to or would result in any other acquisition by any
person of additional securities of the Issuer, or the disposition of securities
of the Issuer.
b) None of the Reporting Persons, nor to the best of their knowledge, any
person listed in Appendix 1 hereto, has any plans or proposals which relate to
or would result in an extraordinary corporate transaction, such as a merger,
reorganization or liquidation, involving the Issuer or any of its subsidiaries.
c) None of the Reporting Persons nor, to the best of their knowledge, any
person listed in Appendix 1 hereto, has any plans or proposals which relate to
or would result in a sale or transfer of a material amount of assets of the
Issuer or any of its subsidiaries.
7
<PAGE>
d) None of the Reporting Persons nor, to the best of their knowledge, any
person listed in Appendix 1 hereto, has any plans or proposals which relate to
or would result in any change in the present board of directors or management of
the Issuer, including any plans or proposals to change the number or term of
directors or to fill any existing vacancies on the board.
In connection with the merger and as contemplated by the Merger
Agreement, the directors of the Issuer were designated as follows: three
individuals specifically named in the Merger Agreement, two persons selected by
Global's board of directors, three persons selected by Impax's board of
directors and two persons mutually selected by the boards of Global and Impax.
In addition, pursuant to the Merger Agreement and Stockholders' Agreement
(attached as Exhibit G thereto), dates as of December 14, 1999, among Global and
certain stockholder signatories thereto, of which the Hsiao Trust and the Hsu
Trust are signatories (the "Stockholders' Agreement"; see Exhibit 5 hereto,
which is incorporated herein by reference), certain stockholders have agreed to
vote certain of their shares in favor of the election of certain directors and
the appointment of certain board observers, for a period ending on December 14,
2002.
Except as set forth above, none of the Reporting Persons nor, to the
best of their knowledge, any person listed in Appendix 1 hereto, has any plans
or proposals which relate to or would result in: (e) any material change in the
present capitalization or dividend policy of the Issuer; (f) any other material
change in the Issuer's business or corporate structure; (g) changes in the
Issuer's charter, By-Laws or instruments corresponding thereto or other actions
which may impede the acquisition of control of the Issuer by any person; (h)
causing a class of securities of the Issuer to be delisted from a national
securities exchange or to cease to be authorized to be quoted in an inter-dealer
quotation system of a registered national securities association; (i) a class of
equity securities of the Issuer becoming eligible for termination of
registration pursuant to Section 12(g)(4) of the Exchange Act; or (j) any action
similar to any of those enumerated above.
The Reporting Persons retain the right to change their investment
intent, to propose one or more possible transactions to the Issuer's board, to
acquire additional shares of Issuer's preferred stock or common stock from time
to time or to sell or otherwise dispose of all or part of the Common Stock
beneficially owned by them in any manner permitted by law. In the event of a
material change in the present plans or intentions of the Reporting Persons, the
Reporting Persons will amend this Schedule 13D to reflect such change, to the
extent required by law.
Item 5. Interest in Securities of the Issuer.
a) As a result of the Merger, the Hsiao Trust acquired 2,601,924 shares of
Common Stock of Issuer. Accordingly, the Hsiao Trust may be deemed to
beneficially own 10.5% of the outstanding shares of Common Stock of Issuer,
which percentage is calculated based upon 24,807,147 shares of Common Stock
reported outstanding by Issuer as of December 14, 1999.
As a result of the Merger, the Hsu Trust acquired 1,334,320 shares of
Common Stock of Issuer. Accordingly, the Hsu Trust may be deemed to beneficially
own 5.4% of the outstanding shares of Common Stock of Issuer, which percentage
is calculated based upon 24,807,147 shares of Common Stock reported outstanding
by Issuer as of December 14, 1999.
As a result of the Merger, Ms. Miller acquired 77,391 shares of Common
Stock of the Issuer. Accordingly, in light of Ms. Miller's role as trustee of
each of the Trusts, Ms. Miller may be deemed to beneficially own 16.2% of the
outstanding shares of Common Stock of Issuer, on an aggregated basis, which
percentage is calculated based upon 24,807,147 shares of Common Stock reported
outstanding by Issuer as of December 14, 1999. Ms. Miller disclaims beneficial
ownership of the Hsiao Trust's and Hsu Trust's shares.
b) The information required by this paragraph is reflected on Lines 7-10
of each Reporting Person's cover page, incorporated herein by reference. The
information required by Items 2 of this Schedule for each person with who the
power to vote or direct a vote or to dispose or direct the disposition is shared
is set forth in Appendix 1 and Appendix 2 hereto.
c) Except as disclosed in Item 3, none of the Reporting Persons has
effected any transactions in the Common Stock during the last 60 days.
d) No other person is known to have the right to receive or the power to
direct the receipt of dividends from, or any proceeds from the sale of, the
shares of Common Stock beneficially owned by any of the Reporting Persons.
8
<PAGE>
e) Not Applicable.
Item 6. Contracts, Arrangements, Understandings or Relationships With Respect
to the Securities of the Issuer.
Each of Ms. Miller, the Hsiao Trust and the Hsu Trust acquired their
shares of Common Stock pursuant to the Merger Agreement.
Pursuant to the Merger Agreement and the Stockholders' Agreement,
certain stockholders have agreed to vote certain of their shares in favor of the
election of certain directors and the appointment of certain board observers,
for a period of time ending on December 14, 2002.
Pursuant to an Escrow Agreement, dated as of December 14, 1999, between
Global, the former Impax shareholders, Charles Hsiao and Larry Hsu as the Seller
Stockholders' Agent (as defined therein) and Continental Stock Transfer & Trust
Company (the "Escrow Agent") (see Exhibit 4 hereto, which is incorporated herein
by reference), the Impax shareholders agreed to place 10% of the Issuer's stock
they were to receive pursuant to the Merger Agreement into an escrow fund
administered by the Escrow Agent. The escrow fund would be available, if
necessary, to indemnify Global pursuant to the indemnification provisions of the
Merger Agreement. The Escrow Agreement provides for the release of the shares
constituting the escrow fund eighteen months after the date of the agreement.
Item 7. Material to be filed as Exhibits.
Exhibit 1 - Joint Filing Agreement.
Exhibit 2 - Agreement and Plan of Merger dated as of July 26, 1999 by and
between Global Pharmaceutical Corporation and Impax Pharmaceuticals,
Inc. (incorporated by reference to Annex A to the Joint Proxy
Statement/Prospectus of Global Pharmaceutical Corporation and Impax
Pharmaceuticals, Inc., filed on November 9, 1999, under SEC File No.
333-90599).
Exhibit 3 - Certificate of Amendment of Restated Certificate of Incorporation
of Global Pharmaceutical Corporation, as filed with the Delaware
Secretary of State on December 14, 1999 (incorporated by reference to
Annex E to the Joint Proxy Statement/Prospectus of Global, filed on
November 9, 1999, under SEC File No. 333-90599).
Exhibit 4 - Escrow Agreement, dated as of December 14, 1999, among Global, the
Impax shareholders, Charles Hsiao and Larry Hsu, in the capacity of the
Seller Stockholders' Agent, and Continental Stock Transfer & Trust
Company, in the capacity of Escrow Agent (incorporated by reference to
Exhibit 99.2 to the Registration Statement on Form S-4 filed by Global
Pharmaceutical Corporation on November 9, 1999, under SEC File No.
333-90599).
Exhibit 5 - Stockholders' Agreement, dated as of December 14, 1999, among
Global Pharmaceutical Corporation and certain stockholder signatories
thereto (incorporated by reference to Exhibit 9.1 to the Registration
Statement on Form S-4 filed by Global Pharmaceutical Corporation on
November 9, 1999, under SEC File No. 333-90599).
Appendix 1 - Address, Organization and Principal Business of Each Reporting
Person Required by Item 2.
Appendix 2 - Information About Each Reporting Person Required by Item 2.
9
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
December 27, 1999
/s/ Laurie A. Miller
------------------------------------
Laurie A. Miller
CHIIN HSIUNG HSIAO CHILDREN IRREVOCABLE TRUST
/s/ Laurie A. Miller, Trustee
------------------------------------
Laurie A. Miller, Trustee
CHUNG-CHIANG HSU CHILDREN IRREVOCABLE TRUST
/s/ Laurie A. Miller, Trustee
------------------------------------
Laurie A. Miller, Trustee
10
<PAGE>
Exhibit 1
JOINT FILING AGREEMENT
Pursuant to and in accordance with Rule 13d-1(k)(1) under the
Securities Exchange Act of 1934, the undersigned hereby agree to jointly file
the Schedule 13D dated December 23, 1999 and any amendments thereto with respect
to the beneficial ownership by each of the undersigned of shares of common stock
of Global Pharmaceutical Corporation. Such joint filings may be executed by one
or more of us on behalf of each of the undersigned.
This Agreement may be executed in any number of counterparts, each of
which shall be deemed an original.
Executed this 23rd day of December, 1999.
/s/ Laurie A. Miller
------------------------------------
Laurie A. Miller
CHIIN HSIUNG HSIAO CHILDREN IRREVOCABLE TRUST
/s/ Laurie A. Miller, Trustee
------------------------------------
Laurie A. Miller, Trustee
CHUNG-CHIANG HSU CHILDREN IRREVOCABLE TRUST
/s/ Laurie A. Miller, Trustee
------------------------------------
Laurie A. Miller, Trustee
11
<PAGE>
APPENDIX 1
ADDRESS, ORGANIZATION AND PRINCIPAL BUSINESS OF EACH REPORTING PERSON
REQUIRED BY ITEM 2 AND OTHER PERSONS REQUIRED BY ITEM 5
<TABLE>
<CAPTION>
PRINCIPAL BUSINESS PRINCIPAL
REPORTING PERSON AND OFFICE PLACE OF ORGANIZATION OCCUPATION
- ---------------- ------------------ --------------------- ----------
<S> <C>
Laurie A. Miller 3542 Oak Knoll Drive California, U.S.A. Attorney
Redwood City, CA 94062
Chiin Hsiung Hsiao Children 30831 Huntwood Avenue California, U.S.A.
Irrevocable Trust Hayward, CA 94544
Chung-Chiang Hsu Children 30831 Huntwood Avenue California, U.S.A.
Irrevocable Trust Hayward, CA 94544
</TABLE>
APPENDIX 2
INFORMATION ABOUT REPORTING PERSONS
REQUIRED BY ITEM 2
CHIIN HSIUNG HSIAO CHILDREN IRREVOCABLE TRUST
Trustee: Laurie A. Miller
Citizenship: United States
Business Address: 3542 Oak Knoll Drive
Redwood City, CA 94062
Beneficiaries:
Name: Bernard Hsiao
Citizenship: United States
Mailing Address: 3210 Hunter Road
Fort Lauderdale, FL 33331
Name: Michael Hsiao
Citizenship: United States
Mailing Address: 3210 Hunter Road
Fort Lauderdale, FL 33331
Name: Kristy Hsiao
Citizenship: United States
Mailing Address: 3210 Hunter Road
Fort Lauderdale, FL 33331
CHUNG-CHIANG HSU CHILDREN IRREVOCABLE TRUST
Trustee: Laurie A. Miller
Citizenship: United States
Business Address: 3542 Oak Knoll Drive
Redwood City, CA 94062
12
<PAGE>
Beneficiaries:
Name: Karl C. Hsu
Citizenship: United States
Mailing Address: 314 Whitegate Court
Lake Forest, IL 60045
Name: Benjamin C. Hsu
Citizenship: United States
Mailing Address: 314 Whitegate Court
Lake Forest, IL 60045
13
